Go to
JCI Insight
Citations to this article
David J. Posey, … , Craig A. Erickson, Christopher J. McDougle
Published January 2, 2008
Citation Information: J Clin Invest. 2008;118(1):6-14. https://doi.org/10.1172/JCI32483.
Citation Information: J Clin Invest. 2008;118(1):6-14. https://doi.org/10.1172/JCI32483.
Abstract
Atypical antipsychotics have become indispensable in the treatment of a variety of symptoms in autism. They are frequently used to treat irritability and associated behaviors including aggression and self injury. They may also be efficacious for hyperactivity and stereotyped behavior. This review presents the rationale for the use of this drug class in autism and reviews the most important studies published on this topic to date. Significant adverse effects, including weight gain and the possibility of tardive dyskinesia, are reviewed. Future research directions are discussed.
Authors
David J. Posey, Kimberly A. Stigler, Craig A. Erickson, Christopher J. McDougle
Total citations by year
Citation information
Citations to this article in year 2016 (3)
| Title and authors | Publication | Year |
|---|---|---|
|
Cochrane Database of Systematic Reviews: Reviews
LE Hirsch, T Pringsheim, T Pringsheim |
Cochrane Database of Systematic Reviews: Reviews | 2016 |
|
Prescription trends in children with pervasive developmental disorders (PDD): A claims data-based study in Japan
M Satoh, T Obara, H Nishigori, N Ooba, Y Morikawa, M Ishikuro, H Metoki, M Kikuya, N Mano |
World Journal of Pediatrics | 2016 |
|
Defining the hidden evidence in autism research. Forty per cent of rigorously designed clinical trials remain unpublished ‐ a cross‐sectional analysis
Mechler K, Hoffmann GF, Dittmann RW, Ries M |
International Journal of Methods in Psychiatric Research | 2016 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)